HKMPY (Hikma Pharmaceuticals) Beginning Cash Position: $217 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKMPY Hikma Pharmaceuticals PLC HKMPY
87 GF Score
Price $46.21
GF Value $56.70
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Hikma Pharmaceuticals Beginning Cash Position?

Hikma Pharmaceuticals HKMPY 87 Beginning Cash Position is $217 Mil as of Jun. 2026. GuruFocus rates HKMPY with a GF Score™ of 87/100 and a GF Value™ of $56.70 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Hikma Pharmaceuticals's Beginning Cash Position for the quarter that ended in Jun. 2026 was $217 Mil.

Hikma Pharmaceuticals's quarterly Beginning Cash Position increased from Jun. 2025 ($188 Mil) to Dec. 2025 ($236 Mil) but then declined from Dec. 2025 ($236 Mil) to Jun. 2026 ($217 Mil).

Hikma Pharmaceuticals's annual Beginning Cash Position declined from Dec. 2023 ($270 Mil) to Dec. 2024 ($205 Mil) and declined from Dec. 2024 ($205 Mil) to Dec. 2025 ($188 Mil).

Hikma Pharmaceuticals Beginning Cash Position Related Terms

Hikma Pharmaceuticals Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Hikma Pharmaceuticals's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hikma Pharmaceuticals Beginning Cash Position Chart

Hikma Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 323.00 371.00 270.00 205.00 188.00

Hikma Pharmaceuticals Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 205.00 236.00 188.00 236.00 217.00
HKMPY
87GF Score
Hikma Pharmaceuticals PLC HKMPY
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hikma Pharmaceuticals Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $217 Mil mean?
Hikma Pharmaceuticals (HKMPY) has a Beginning Cash Position of $217 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Hikma Pharmaceuticals and its competitors.
Is Hikma Pharmaceuticals' Beginning Cash Position too high?
Hikma Pharmaceuticals' current Beginning Cash Position is $217 Mil. Overall, Hikma Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' Beginning Cash Position compare to ZTS and UTHR?
Hikma Pharmaceuticals' Beginning Cash Position of $217 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Hikma Pharmaceuticals and its competitors. Hikma Pharmaceuticals's current Beginning Cash Position is $217 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPY) is currently considered Modestly Undervalued. The stock's GF Value™ is $56.70, compared to a current price of $46.21 — trading 18.5% below its estimated fair value. The current Beginning Cash Position is $217 Mil. Hikma Pharmaceuticals' overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPY), the current Beginning Cash Position is $217 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hikma Pharmaceuticals (HKMPY) Overvalued in 2026?

Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued. The current stock price of $46.21 is trading 18.5% below its estimated GF Value™ of $56.70. GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for HKMPY:

  • Beginning Cash Position: $217 Mil
  • GF Value™: $56.70 vs. price of $46.21 (18.5% below fair value)
  • GF Score™: 87/100 with 6 warning signs

No single metric tells the full story. See the HKMPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hikma Pharmaceuticals Business Description

Address 10 Portman Square, London, GBR, W1H 6AZ
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
87GF Score

Get the complete analysis for HKMPY

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$46.21
Price
$56.70
GF Value